Pfizer applies science and its global resources to bring therapies to people that extend and significantly improve their lives. It strives to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with its responsibility as one of the world's premier innovative biopharmaceutical companies, it collaborates with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, it has worked to make a difference for all who rely on it. It routinely posts information that may be important to investors on its website at www.Pfizer.com.
235 E 42nd St
New York, New York 10017-5703
Phone: 12125732323
www.pfizer.com
We recently compiled a list of the 10 Best GLP-1 and Weight Loss Stocks to Buy Now. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against the other GLP-1 and weight loss stocks. According to WHO, more than one billion people worldwide are obese, including 650 million adults, […]
Betting on dividend stocks , especially in the long run, can strengthen your portfolio. To begin, dividend-paying companies offer stable returns, ensuring sustainable cash flow even in volatile markets. Most of these companies continually increase their dividend payouts over the years. These dividends provide a consistent income stream that requires no effort from you. Many major corporations also initiate frequent stock buybacks, which enhance shareholder value. This combination of reliability and easy earnings makes dividend stocks appealing to individuals looking for passive income. Moreover, these dividend stocks are often backed by financially strong companies with a history of performance. This means you’re not just getting regular gains but putting your money into businesses with solid foundations. Adding them to your portfolio sets you up for a winning mix of income and growth. This balanced approach can lead to sustainable financial success. Now, let’s look at three companies that can help you achieve just that.
Eli Lilly (NYSE: LLY ) stock rose 13% overnight after it beat analyst estimates and raised guidance. The company’s GLP-1 drugs for diabetes and weight loss, Zepbound and Mounjaro, propelled the results. The company reported net income of $2.97 billion, $3.28 per share fully diluted, on revenue of $11.3 billion . Lilly also raised its full-year revenue guidance to $45.4 billion-$46.6 billion and earnings per share guidance to $15.10-$15.40 per share . The market responded as if Lilly was selling artificial intelligence (AI) chips. Shares jumped over 13% overnight. Before the market opened, they were trading at over $874, and the market capitalization rose to over $825 billion. The Diabetes Gold Rush Lilly could predict future success after the Food and Drug Administration (FDA) announced that the drugmaker has resolved its two-year-long shortages of diabetes drugs. By the end of the first quarter, the company had seven sites producing the drugs. Despite shortages, Mounjaro had sales of $3.1 billion in the second quarter and Zepbound over $1.2 billion.
Can this struggling stock turn things around?
High-growth dividend stocks are essential for assembling a robust income portfolio. These stocks offer the dual benefits of capital appreciation and regular income through dividends. One needs to focus on companies with solid fundamentals that derive constant growth and profitability to identify the top picks. Investing in dividend stocks is a strategic way of securing long-term financial returns, mainly if the stocks at issue belong to sectors known for stability and growth. This article looks at the top three dividend stocks within the communication, real estate, and healthcare sectors, each chosen for their potential for solid growth and a dependable dividend yield. The communication sector includes companies that are most likely to have a stable cash flow and high barriers to entry, thus constituting a reliable group of dividend payers. Real estate investment, primarily through REITs, is also quite attractive in paying dividends, driven by rental income and property appreciation. The healthcare sector is usually considered one of the most resilient and has one of the strongest demands, given a close-to-bursting aging demographic and recent advances in medical technology.
Markets are in turmoil as the selloff in mega-cap technology stocks that began in July accelerates. On Aug. 5, the mega-cap tech companies known as the “Magnificent Seven,” generally considered among the best stocks to buy, lost a combined $1 trillion of value amid a global stock market rout. The selloff saw the Dow Jones Industrial Average shed more than 1,000 points in a single day and the tech-heavy Nasdaq fall into a correction, defined as a 10% drop from recent highs. Japan’s Nikkei 225 index plummeted 12% for its worst day since the 1987 “Black Monday” crash on Wall Street. The sharp selloff has been caused by fears that the U.S. economy is entering a recession and the U.S. Federal Reserve has been too slow to start lowering interest rates. The result is that the Cboe Volatility Index , commonly known as Wall Street’s “ fear gauge ,” is at its highest level since the pandemic struck in 2020. So what’s an investor to do amid the current market turmoil? Look for bargains and the best stocks to buy on the cheap, of course.
Investing in biotech stocks with promising pipelines has to be the most exciting area of the market. A successful drug approval can not only unveil a blockbuster treatment worth billions of dollars, but it can literally change people’s lives for the better. Yet the biotech landscape is also littered with failure. Drugs that previously held so much promise end up proving worthless. Biotech stocks that soared on the potential for approval end up crashing and burning with investors losing their money. That’s why you must perform extreme due diligence before investing in biotech stocks with seemingly promising pipelines. The three companies below are excellent places to start. They are all established biotechs with approved therapies on the market. Yet, they also have robust pipelines possessing at least one potential blockbuster, and in some cases, several. BioNTech (BNTX) Source: Palatinate Stock / Shutterstock.com BioNTech (NASDAQ: BNTX ) exploded into the public consciousness because of its Covid-19 vaccine, produced in partnership with Pfizer (NYSE: PFE ).
Amid the stock market turmoil, wagering on the best biotech stocks could be a savvy move. The stock market has been tumultuous lately, which could spur a pivot toward defensive biotech stocks. Since biotech companies develop essential drugs and therapies, they often navigate independently from the broader market. Hence, biotech stocks offer promising investment opportunities, especially those pioneering innovative healthcare solutions. Moreover, as global health priorities shift and demand for advanced therapeutics climbs, certain biotech firms will likely outperform others. Additionally, the FDA’s streamlined pathway for developing critical medications enhances the prospects for the market’s finest. Also, the best biotech stocks can shell out a boatload of cash in developing new therapies, which, if approved, could generate billions in incremental sales. That said, the spotlight shines on these three best biotech stocks poised for substantial long-term growth. Each boasts healthy fundamentals and an innovative pipeline that promises to meet and exceed market expectations.
